Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore TM / SemaPhore TM delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-4... Altamira Therapeutics is dedicated to developing RNA-based therapeutics for extrahepatic targets (OligoPhore TM / SemaPhore TM delivery platforms). The Company currently has two flagship siRNA programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Show more
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from...
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract...
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new...
Hamilton, Bermuda, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA...
Hamilton, Bermuda, Sept. 19, 2024 (GLOBE NEWSWIRE) -- $4 million upfront with up to an additional $8 million of aggregate gross proceeds upon the exercise in full for cash of milestone-linked...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0184 | -4.18657565415 | 0.4395 | 0.4497 | 0.4 | 47810 | 0.4158934 | CS |
| 4 | -0.0789 | -15.78 | 0.5 | 0.62 | 0.4 | 108324 | 0.43855743 | CS |
| 12 | -0.4789 | -53.2111111111 | 0.9 | 0.9384 | 0.4 | 78478 | 0.56467508 | CS |
| 26 | -1.1389 | -73.0064102564 | 1.56 | 1.59 | 0.4 | 259210 | 0.98204226 | CS |
| 52 | -6.2049 | -93.6447328705 | 6.626 | 12.8 | 0.4 | 1450293 | 5.07272486 | CS |
| 156 | -651.5789 | -99.9354141104 | 652 | 920 | 0.4 | 2242940 | 73.519793 | CS |
| 260 | -239.5789 | -99.8245416667 | 240 | 1548 | 0.4 | 1848102 | 183.84400923 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
